Mitchell GA, Grompe M, Lambert M. Hypertyrosinemia. In: Valle D, Beaudet AL, Vogelstein B, et al., eds. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; 2023.
[2]
Scriver CR, Kaufman S, Eisensmith RC, Woo SLC. The hyperphenylalaninemias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. McGraw-Hill; 2001:1667-1724.
[3]
de Jongh R, Vaidya N, Kemperman J, et al. Transient tyrosinemia of the newborn: a benign condition. J Pediatr Gastroenterol Nutr. 2002;34(5):551-555.
[4]
Levy HL, Makris M. Neonatal screening for metabolic disorders. In: Avery's Diseases of the Newborn. 10th ed. Elsevier; 2018:145-162.
[5]
American Academy of Pediatrics Committee on Genetics. Health supervision for children with phenylketonuria. Pediatrics. 2008;121(2):404-409.
[6]
van Spronsen FJ, Enns CA. Future treatment strategies in phenylketonuria. Mol Genet Metab. 2010;100(4):345-352.
[7]
Harding CO, Blau N. Advances in the treatment of phenylketonuria: towards a paradigm shift. J Inherit Metab Dis. 2020;43(4):701-710.
[8]
Waisbren SE, Albers S, Amato S, et al. Effect of high-dose tyrosine supplementation on neuropsychological functioning in patients with phenylketonuria. J Pediatr. 2003;143(4):458-465.